Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Certification | 2 | 2017 | 49 | 0.720 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 16 | 0.720 |
Why?
|
| General Surgery | 2 | 2017 | 49 | 0.710 |
Why?
|
| Test Taking Skills | 1 | 2017 | 2 | 0.610 |
Why?
|
| Internship and Residency | 2 | 2017 | 211 | 0.570 |
Why?
|
| Clinical Competence | 1 | 2017 | 230 | 0.520 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 125 | 0.440 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 19 | 0.400 |
Why?
|
| Organ Transplantation | 4 | 2021 | 35 | 0.390 |
Why?
|
| Liver Transplantation | 4 | 2014 | 79 | 0.360 |
Why?
|
| Tissue and Organ Procurement | 4 | 2009 | 34 | 0.280 |
Why?
|
| Educational Measurement | 2 | 2017 | 59 | 0.280 |
Why?
|
| Graft Rejection | 4 | 2009 | 76 | 0.270 |
Why?
|
| Aneurysm | 1 | 2022 | 11 | 0.210 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 9 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.210 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 47 | 0.200 |
Why?
|
| Renal Dialysis | 3 | 2022 | 113 | 0.200 |
Why?
|
| Graft Survival | 6 | 2014 | 98 | 0.200 |
Why?
|
| Surgical Instruments | 1 | 2020 | 25 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2020 | 70 | 0.180 |
Why?
|
| Adult | 14 | 2020 | 8604 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2020 | 141 | 0.180 |
Why?
|
| Intestines | 2 | 2008 | 107 | 0.150 |
Why?
|
| Humans | 21 | 2022 | 29361 | 0.150 |
Why?
|
| Simulation Training | 1 | 2017 | 34 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2022 | 3273 | 0.150 |
Why?
|
| Male | 15 | 2020 | 15637 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2017 | 132 | 0.140 |
Why?
|
| United States | 4 | 2017 | 2332 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 79 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 142 | 0.140 |
Why?
|
| Curriculum | 1 | 2017 | 155 | 0.140 |
Why?
|
| Treatment Outcome | 9 | 2022 | 3476 | 0.140 |
Why?
|
| Female | 14 | 2020 | 16211 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2017 | 158 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 60 | 0.120 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 3 | 0.120 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 9 | 0.120 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 19 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 29 | 0.110 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 39 | 0.110 |
Why?
|
| Time Factors | 4 | 2022 | 1618 | 0.110 |
Why?
|
| Stents | 1 | 2013 | 76 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 161 | 0.110 |
Why?
|
| Middle Aged | 12 | 2020 | 9823 | 0.110 |
Why?
|
| Vascular Patency | 2 | 2022 | 15 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 277 | 0.100 |
Why?
|
| Liver | 2 | 2009 | 173 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 132 | 0.100 |
Why?
|
| Child | 6 | 2009 | 1345 | 0.100 |
Why?
|
| Stomach | 1 | 2009 | 18 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 24 | 0.090 |
Why?
|
| Living Donors | 1 | 2009 | 8 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2009 | 3 | 0.090 |
Why?
|
| Leucine | 1 | 2009 | 15 | 0.090 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 7 | 0.090 |
Why?
|
| Colonic Diseases | 1 | 2009 | 12 | 0.090 |
Why?
|
| Hypoglycemia | 1 | 2009 | 14 | 0.090 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 27 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 4 | 0.080 |
Why?
|
| Pancreatectomy | 1 | 2008 | 10 | 0.080 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 20 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 16 | 0.080 |
Why?
|
| Colon | 1 | 2009 | 148 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 4 | 0.080 |
Why?
|
| Hysterectomy | 1 | 2008 | 19 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 69 | 0.080 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 12 | 0.080 |
Why?
|
| Lung Transplantation | 1 | 2007 | 18 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2008 | 145 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 9447 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 74 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 137 | 0.070 |
Why?
|
| Adolescent | 5 | 2009 | 2280 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 162 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2009 | 641 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2014 | 15 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 24 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 10 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 21 | 0.050 |
Why?
|
| Carcinoma | 1 | 2002 | 57 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 45 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 23 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 32 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 36 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 142 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 189 | 0.050 |
Why?
|
| Risk Factors | 2 | 2022 | 2446 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 144 | 0.050 |
Why?
|
| Kidney | 1 | 2021 | 173 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2014 | 298 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 756 | 0.040 |
Why?
|
| Insulin | 2 | 2008 | 92 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 957 | 0.040 |
Why?
|
| Infant | 2 | 2008 | 531 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 148 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1829 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 1935 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 330 | 0.030 |
Why?
|
| Probability | 2 | 2002 | 94 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 340 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 4851 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 502 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 34 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 16 | 0.020 |
Why?
|
| Prognosis | 2 | 2002 | 840 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 52 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 1 | 0.020 |
Why?
|
| Procaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2008 | 5 | 0.020 |
Why?
|
| Amylases | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mannitol | 1 | 2008 | 12 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 4 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 241 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 30 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Indiana | 1 | 2008 | 17 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 13 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 48 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 53 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 38 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 59 | 0.020 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 3 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 7 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 112 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 28 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 359 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 56 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 234 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 260 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 788 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 495 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 181 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 678 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 1113 | 0.020 |
Why?
|
| Reoperation | 1 | 2008 | 933 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 26 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 46 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 58 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 96 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 68 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 321 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 226 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 324 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 349 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 521 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 553 | 0.010 |
Why?
|